Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Cash from Financing Activities: 2022-2025

Historic Cash from Financing Activities for Stoke Therapeutics (STOK) over the last 4 years, with Sep 2025 value amounting to $3.1 million.

  • Stoke Therapeutics' Cash from Financing Activities fell 61.76% to $3.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.6 million, marking a year-over-year decrease of 95.93%. This contributed to the annual value of $131.1 million for FY2024, which is 147.31% up from last year.
  • As of Q3 2025, Stoke Therapeutics' Cash from Financing Activities stood at $3.1 million, which was up 463.18% from $554,000 recorded in Q2 2025.
  • In the past 5 years, Stoke Therapeutics' Cash from Financing Activities ranged from a high of $120.7 million in Q2 2024 and a low of $43,000 during Q4 2022.
  • In the last 3 years, Stoke Therapeutics' Cash from Financing Activities had a median value of $1.7 million in 2024 and averaged $17.2 million.
  • In the last 5 years, Stoke Therapeutics' Cash from Financing Activities skyrocketed by 251,254.17% in 2024 and then tumbled by 99.54% in 2025.
  • Quarterly analysis of 4 years shows Stoke Therapeutics' Cash from Financing Activities stood at $43,000 in 2022, then surged by 16,976.74% to $7.3 million in 2023, then plummeted by 92.26% to $568,000 in 2024, then tumbled by 61.76% to $3.1 million in 2025.
  • Its Cash from Financing Activities was $3.1 million in Q3 2025, compared to $554,000 in Q2 2025 and $1.4 million in Q1 2025.